MET and neoplasm: Target 2, which resided 1.06 mm from target 1, exhibited tumor cells containing both strongly amplified MET and CCND1, 3 to 4 copies of EGFR, 3 to 4 copies of FGFR2, and loss of both copies of the genes encoding PD-L1/PD-L2.